NorthSea Therapeutics
Clinical-stage biopharmaceutical company focused on the development of structurally engineered fatty acids (SEFAs).
Clinical-stage biopharmaceutical company focused on the development of structurally engineered fatty acids (SEFAs).
NorthSea Therapeutics is a clinical-stage biopharmaceutical company headquartered in The Netherlands. Since its founding in 2017, the company has been dedicated to developing novel and innovative therapeutic strategies for NASH and other metabolic, inflammatory, and fibrotic diseases. NorthSea Therapeutics focuses on the development of structurally engineered fatty acids (SEFAs). The company recently secured a significant $80.00M Series C investment on 17 December 2021. The investment was led by a consortium of prominent investors including Hercules Capital, BioGeneration Ventures, Forbion, Sofinnova Investments, New Science Ventures, Novo Seeds, VenBio Partners, and Ysios Capital. With its strong focus on addressing critical unmet medical needs, NorthSea Therapeutics is well-positioned to make an impact in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $80.00M | 8 |
|
17 Dec 2021 |
| Series B | €36.00M | 2 |
|
08 Jan 2020 |
| Venture Round | Unknown | - | 01 Jan 2019 | |
| Series A | €25.00M | - | 12 Dec 2017 |
No recent news or press coverage available for NorthSea Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
